Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma (Q33375694)

26 July 2017

1 reference

title

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma (English)

1 reference

26 July 2017

Madeleine Duvic

1

1 reference

PubMed ID

17594194

26 July 2017

Jenny Vu

series ordinal

2

1 reference

PubMed ID

17594194

26 July 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Investigational Drugs

26 July 2017

1 reference

26 July 2017

16

1 reference

26 July 2017

1111-1120

1 reference

26 July 2017

7

1 reference

The pathogenesis of mycosis fungoides

26 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Clinicopathological spectrum of mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Cutaneous T-cell lymphoma: a paradigm for biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Comparative genomics of the class 4 histone deacetylase family indicates a complex evolutionary history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

The Sir2 family of protein deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase inhibitors: latest developments, trends and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase inhibitors: discovery and development as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase inhibitors in programmed cell death and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Histone deacetylase inhibitors--a new tool to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

STAT proteins as novel targets for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1111

10.1517/13543784.16.7.1111

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference

PubMed ID

17594194